Assessment of Filamin-A Levels in Patients with Acromegaly Only and those Associated with Diabetes Mellitus

Hiba Ghassan Rajab; Shatha Mohammed Jawad Al-Khateeb; Abbas Mahdi Rahmah

doi:10.54133/ajms.v8i2.1822

Authors

Hiba Ghassan Rajab Department of Pharmacology, College of Medicine, University of Baghdad, Baghdad, Iraq; Department of Chemistry and Biochemistry, College of Medicine, Mustansiriyah University, Baghdad, Iraq https://orcid.org/0009-0003-7677-7836
Shatha Mohammed Jawad Al-Khateeb Department of Chemistry and Biochemistry, College of Medicine, Mustansiriyah University, Baghdad, Iraq
Abbas Mahdi Rahmah National Diabetes Center, Mustansiriyah University, Baghdad, Iraq

DOI:

https://doi.org/10.54133/ajms.v8i2.1822

Keywords:

Acromegaly, Actin-binding protein, Diabetes mellitus, FLNA, Pituitary adenoma

Abstract

Background: Acromegaly is a rare endocrine disorder characterized by elevated levels of insulin-like growth factor-1 and growth hormone, which are typically brought on by a somatotroph adenoma of the pituitary gland. It has an incidence of 4 per million annually and a prevalence of 40 per million. The elevated IGF-1 levels cause somatic growth and metabolic effects, with subsequently increased morbidity and mortality, particularly when GH and IGF-1 levels remain persistently elevated. Objective: To evaluate the levels of filamin-A (FLNA) in patients with acromegaly with and without diabetes mellitus type 2 (T2DM) compared to a control group. Methods: In this case-control study, one hundred patients with acromegaly registered at the National Diabetes Center, Mustansiriyah University, were enrolled in the study. 76 participants as control. All recruited participants have given oral consent to participate in the study, which was conducted from February 2024 to August 2024. Results: The age distribution differences were not statistically significant. The gender distribution showed 47 females and 53 males in the acromegaly group. The FLNA level was higher among patients compared to controls and showed the highest level in acromegaly and DM (687.24 ng/L), followed by acromegaly without DM (359.39 ng/L), controls with DM (205.96 ng/L), and controls without DM (143.29 ng/L). Conclusions: The results showed that serum FLNA was elevated in patients with acromegaly in comparison to the control group and in the T2DM group versus those without T2DM.

Downloads

Download data is not yet available.

References

Selman NA, Rahma AM, Ali AY, Abed HK. Thyroid nodules of Iraqi patients with acromegaly. Indian J Forensic Med Toxicol. 2020;14(1):821-827. doi: 10.37506/ijfmt.v14i1.154. DOI: https://doi.org/10.37506/ijfmt.v14i1.154

Hammood SD, Ali EA, Rahmah AM. Evaluation of beta-arrestin levels in acromegaly patients: A comparison of patients with and without obstructive sleep apnea. Al-Rafidain J Med Sci. 2024;6(1):86-90. doi: 10.54133/ajms.v6i1.479. DOI: https://doi.org/10.54133/ajms.v6i1.479

Hammood SD, Ali EA, Rahmah AM. Brain natriuretic peptide in patients with acromegaly: A comparative study between those with and without obstructive sleep apnea. Mustansiriyah Med J. 2024;23(1):45-50. doi: 10.4103/mj.mj_17_24. DOI: https://doi.org/10.4103/mj.mj_17_24

Lawrence L, Alkwatli K, Bena J, Prayson R, Kshettry V, Recinos P, et al. Acromegaly: a clinical perspective. Clin Diabetes Endocrinol. 2020;6. doi: 10.1186/s40842-020-00104-5. DOI: https://doi.org/10.1186/s40842-020-00104-5

Akirov A, Masri-Iraqi H, Dotan I, Shimon I. The biochemical diagnosis of acromegaly. J Clin Med. 2021;9(5). doi: 10.3390/jcm10051147. DOI: https://doi.org/10.3390/jcm10051147

Seejore K, Alavi SA, Pearson SM, Robins JM, Alromhain B, Sheikh A, et al. Post-operative volumes following endoscopic surgery for non-functioning pituitary macroadenomas are predictive of further intervention, but not endocrine outcomes. BMC Endocr Disord. 2021;21:116. doi: 10.1186/s12902-021-00777-8. DOI: https://doi.org/10.1186/s12902-021-00777-8

Malek FK, Abbas SA, Abed BA. Evaluation of the activity of arginase and some biochemical parameters in sera of patients with acromegaly. Baghdad Sci J. 2024;21(12):3709-3715. doi: 10.21123/bsj.2024.8784. DOI: https://doi.org/10.21123/bsj.2024.8784

Maione L, Chanson P, (Eds.), Acromegaly. In: Pituitary Adenomas: The European Neuroendocrine Association’s Young Researcher Committee Overview 2022 Jan 31 (pp. 127-171). doi: 10.1007/978-3-319-99817-6_20. DOI: https://doi.org/10.1007/978-3-030-90475-3_5

Yang H, Tan H, Huang H, Li J. Advances in research on the cardiovascular complications of acromegaly. Fron Oncol. 2021:2. doi: 10.3389/fonc.2021.640999. DOI: https://doi.org/10.3389/fonc.2021.640999

Peverelli E, Giardino E, Treppiedi D, Vitali E, Cambiaghi V, Locatelli M, et al. Filamin A (FLNA) plays an essential role in somatostatin receptor 2 (SST2) signaling and stabilization after agonist stimulation in human and rat somatotroph tumor cells. Endocrinology. 2014;155(8). doi: 10.1210/en.2014-1063. DOI: https://doi.org/10.1210/en.2014-1063

Tahir NT, Al-Khateeb SM, Akram RS. Preptin as a potential marker in Iraqi newly diagnosed T2DM and T2DM with cardiovascular disease. J Contemp Med Sci. 2024;10(2). doi: 10.22317/jcms.v10i2.1490. DOI: https://doi.org/10.22317/jcms.v10i2.1490

Shao QQ, Zhang TP, Zhao WJ, Liu ZW, You L, Zhou L, et al. Filamin A: insights into its exact role in cancers. Pathol Oncol Res. 2016;22:245–252. doi 10.1007/s12253-015-9980-1. DOI: https://doi.org/10.1007/s12253-015-9980-1

Spada A, Mantovani G, Lania AG, Treppiedi D, Mangili F, Catalano R, et al. Pituitary tumors: genetic and molecular factors underlying pathogenesis and clinical behavior. Neuroendocrinology. 2022;112:15–33. doi: 10.1159/000514862. DOI: https://doi.org/10.1159/000514862

Zhou J, Kang X, An H, Lv Y, Liu X. The function and pathogenic mechanism of filamin A. Gene. 2021 Jun 5; 784. doi.org/10.1016/j.gene. DOI: https://doi.org/10.1016/j.gene.2021.145575

Treppiedi D, Catalano R, Mangili F, Mantovani G, Peverelli E. Role of filamin A in the pathogenesis of neuroendocrine tumors and adrenal cancer. Endocrine Oncol. 2022;2(1):R143-152. doi: 10.1530/EO-22-0055.

Mantovani G, Treppiedi D, Giardino E, Catalano R, Mangili F, Vercesi P, et al. Cytoskeleton actin-binding proteins in clinical behavior of pituitary tumors. Endocrine-Related Cancer. 2019;26(2):R95-108. doi: 10.1530/ERC-18-0442. DOI: https://doi.org/10.1530/ERC-18-0442

Fieffe S, Morange I, Petrossians P, Chanson P, Rohmer V, Cortet C, et al. Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. Eur J Endocrinol. 2011;164(6):877-884. doi: 10.1530/EJE-10-1050. DOI: https://doi.org/10.1530/EJE-10-1050

Li M, Peng L, Wang Z, Liu L, Cao M, Cui J, et al. Roles of the cytoskeleton in human diseases. Mol Biol Rep. 2023;50(3):2847-2856. doi: 10.1007/s11033-022-08025-5. DOI: https://doi.org/10.1007/s11033-022-08025-5

Treppiedi D, Catalano R, Mangili F, Mantovani G, Peverelli E. Role of filamin A in the pathogenesis of neuroendocrine tumors and adrenal cancer. Endocrine Oncol. 2022;2(1):R143-52. doi: 10.1530/EO-22-0055. DOI: https://doi.org/10.1530/EO-22-0055

Treppiedi D, Mantovani G, Peverelli E, Sungkaworn T, Zabel U, Giardino E, et al. High-resolution spatiotemporal analysis of somatostatin receptor type 2 (SSTR2)-Filamin A (FLNA) interaction by single-molecule imaging. Endocrine Abstracts. 2016;13(1);41. doi: 10.1530/endoabs.41.GP120. DOI: https://doi.org/10.1530/endoabs.41.GP120

Hannon AM, Thompson CJ, Sherlock M. Diabetes in patients with acromegaly. Curr Diabetes Rep. 2017; 17:1-8. doi: 10.1007/s11892-017-0838-7. DOI: https://doi.org/10.1007/s11892-017-0838-7